Related Experiment Video
Updated: May 31, 2026
11:47
A Novel in vivo Gene Transfer Technique and in vitro Cell Based Assays for the Study of Bone Loss in Musculoskeletal Disorders
Published on: June 8, 2014
Omentin-1 exerts bone-sparing effect in ovariectomized mice
1Institute of Endocrinology and Metabolism, Second Xiangya Hospital of Central South University, 139# Middle Renmin Road, Changsha, Hunan 410011, People's Republic of China.
Summary
Omentin-1, a cytokine, was found to inhibit osteoblast differentiation and reduce osteoclast formation by modulating OPG and RANKL. This suggests omentin-1 may protect against bone loss from estrogen deficiency.
Area of Science:
- Endocrinology
- Bone Biology
- Metabolic Research
Background:
- Omentin-1 (intelectin-1) is a visceral adipose tissue-derived cytokine abundant in plasma.
- Its role in bone metabolism was previously uncharacterized.
Purpose of the Study:
- To investigate the effects of omentin-1 on bone metabolism.
- To determine omentin-1's potential in ameliorating bone loss.
Main Methods:
- In vitro assessment of osteoblast differentiation and osteoclast formation.
- Co-culture systems of osteoblasts and osteoclast precursors.
- In vivo studies using adenovirus-mediated omentin-1 delivery in ovariectomized mice.
Main Results:
- Omentin-1 inhibited osteoblast differentiation in vitro.
- Omentin-1 reduced osteoclast formation by increasing osteoprotegerin (OPG) and decreasing receptor activator for nuclear factor κB ligand (RANKL) production in osteoblasts.
- Adenovirus-mediated omentin-1 overexpression in vivo restored bone mineral density and bone strength in ovariectomized mice.
Conclusions:
- Omentin-1 ameliorates bone loss associated with estrogen deficiency.
- This effect is mediated by downregulating the RANKL/OPG ratio.
